Navigation Links
Transporter could help breast cancer cells commit suicide
Date:2/17/2009

AUGUSTA, Ga. Researchers are trying to open a door for a killer that breast cancer cells shut out.

"If we can figure out how to do that, we could have a new therapeutic target for fighting breast cancer," says Dr. Thangaraju Muthusamy, assistant professor of biochemistry and molecular biology in the Medical College of Georgia School of Medicine.

Pyruvate is a metabolite in the blood that is lethal to rapidly-multiplying cells, like cancer, and transporters bring substances like pyruvate inside cells. Since breast cancer cells won't allow pyruvate in, MCG researchers looked to a healthy group of rapidly-dividing breast cells that do let in a similar killer.

For breastfeeding, breast tissue must increase in size to allow milk production, says Dr. Vadivel Ganapathy, chair of the Department of Biochemistry and Molecular Biology in the School of Medicine. When breast-feeding stops, milk accumulates, and butyrate, a short-chain fatty acid similar to pyruvate, starts getting inside the cells. Breast size is reduced and lactation is halted via this process known as involution.

"The normal expansion of breast tissue during lactation is similar to breast cancer when tumors grow and multiply," Dr. Muthusamy says. "But the cell death that occurs in normal breast tissue during involution does not occur in breast cancer. Tumor cells are smart; they silence the transporter to avoid death. No transporter means no pyruvate is getting into the cells."

With new grants from the Department of Defense and the National Cancer Institute totaling $2.3 million, researchers will try to force cancer cells to express the transporter and open the door for pyruvate.


'/>"/>

Contact: Jennifer Hilliard
jhilliard@mcg.edu
706-721-8604
Medical College of Georgia
Source:Eurekalert  

Page: 1

Related medicine news :

1. Transporters may help delay diabetes-related retinal damage
2. SNPs of ABC transporter genes linked to lung cancer risk
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. HIV denialists spread misinformation online -- consequences could be deadly; and more
6. Virus Could Help Drive Obesity
7. Discovery of sugar sensor in intestine could benefit diabetes
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
10. High-risk behaviors could lead to HIV epidemic in Afghanistan
11. Chinas 1-child policy could backfire on its elderly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transporter could help breast cancer cells commit suicide
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... for-profit and nonprofit hospitals and health systems in the nation and help their ... institutions, led professional organizations and been instrumental in developing successful hospital and health ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology: